[go: up one dir, main page]

MX2018006828A - Usos de poblaciones expandidas de celulas madre/progenitoras hematopoyeticas. - Google Patents

Usos de poblaciones expandidas de celulas madre/progenitoras hematopoyeticas.

Info

Publication number
MX2018006828A
MX2018006828A MX2018006828A MX2018006828A MX2018006828A MX 2018006828 A MX2018006828 A MX 2018006828A MX 2018006828 A MX2018006828 A MX 2018006828A MX 2018006828 A MX2018006828 A MX 2018006828A MX 2018006828 A MX2018006828 A MX 2018006828A
Authority
MX
Mexico
Prior art keywords
progenitor cells
hematopoietic stem
reduce
expanded populations
following
Prior art date
Application number
MX2018006828A
Other languages
English (en)
Inventor
Delaney Colleen
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of MX2018006828A publication Critical patent/MX2018006828A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen los usos de células madre/progenitoras hematopoyéticas (HSPC) de sangre de cordón expandidas. Ejemplos incluyen reducir el rechazo de trasplante, inducir inmunotolerancia, reducir la alimentación de nutrición parenteral total (TPN), el uso de opioides, la mucositis y la hospitalización después de un procedimiento médico y reducir la enfermedad de injerto versus huésped (GVHD) después de un trasplante alogénico.
MX2018006828A 2015-12-04 2016-12-05 Usos de poblaciones expandidas de celulas madre/progenitoras hematopoyeticas. MX2018006828A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263573P 2015-12-04 2015-12-04
US201562263470P 2015-12-04 2015-12-04
PCT/US2016/064908 WO2017096347A1 (en) 2015-12-04 2016-12-05 Uses of expanded populations of hematopoietic stem/progenitor cells

Publications (1)

Publication Number Publication Date
MX2018006828A true MX2018006828A (es) 2018-08-09

Family

ID=58797992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006828A MX2018006828A (es) 2015-12-04 2016-12-05 Usos de poblaciones expandidas de celulas madre/progenitoras hematopoyeticas.

Country Status (11)

Country Link
US (1) US10813949B2 (es)
EP (1) EP3384006A4 (es)
JP (2) JP2018537472A (es)
KR (1) KR20180085018A (es)
CN (1) CN108473949A (es)
AU (1) AU2016364934A1 (es)
BR (1) BR112018011327A2 (es)
CA (1) CA3005767A1 (es)
MX (1) MX2018006828A (es)
RU (1) RU2747728C2 (es)
WO (1) WO2017096347A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110621321B (zh) 2017-03-15 2024-06-21 浩康生物系统公司 用于造血干细胞移植的组合物和方法
IL270678B2 (en) 2017-05-16 2024-09-01 Gamida Cell Ltd Selection and use of umbilical cord cell fractions suitable for transplantation
CA3064055A1 (en) 2017-05-16 2018-11-22 Gamida-Cell Ltd. Selection and use of umbilical cord cell fractions suitable for transplantation
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CA3137570A1 (en) 2019-05-15 2020-11-19 Stemcyte Inc. High concentration cell packaging and shipping
CN110564687B (zh) * 2019-11-05 2020-04-03 诺未科技（北京）有限公司 用于扩增造血干细胞的组合物、培养基、方法和试剂盒
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
CN116583594B (zh) 2020-10-14 2025-05-23 奥瑟姆健康公司 用于骨髓的提取和低温保藏的系统和方法
WO2022133282A1 (en) 2020-12-18 2022-06-23 Ossium Health, Inc. Methods of cell therapies
US20220323547A1 (en) * 2021-04-13 2022-10-13 Therapeutic Solutions International, Inc. Amelioration and Treatment of Opioid Addiction
WO2023283404A1 (en) * 2021-07-09 2023-01-12 Temple University - Of The Commonwealth System Of Higher Education Myocardial wound healing post ischemic injury

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5856441A (en) 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
US5869282A (en) 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
WO1993012141A1 (en) 1991-12-11 1993-06-24 Yale University Nucleotide and protein sequences of the serrate gene and methods based thereon
AU7404494A (en) 1993-07-21 1995-02-20 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
AU4236296A (en) * 1994-11-10 1996-06-06 Fred Hutchinson Cancer Research Center Intrathymic stem cell implantation
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US6544506B2 (en) * 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
US20020132343A1 (en) * 2001-03-19 2002-09-19 Clark Lum System and method for delivering umbilical cord-derived tissue-matched stem cells for transplantation
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
CA2585343C (en) 2004-10-25 2016-06-21 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
CN101421393B (zh) 2006-02-14 2013-08-14 塞勒兰特治疗公司 提高造血干细胞植入的方法和组合物
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
PT2120977E (pt) * 2007-02-12 2013-09-16 Anthrogenesis Corp Tratamento de doenças inflamatórias utilizando células estaminais da placenta
CA3090548C (en) * 2010-04-09 2025-09-02 Fred Hutchinson Cancer Research Center COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION
EP2555782A1 (en) * 2010-04-09 2013-02-13 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
HK1203081A1 (en) * 2011-12-08 2015-10-16 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
ES2811529T3 (es) * 2011-12-22 2021-03-12 Yeda Res & Dev Una terapia de combinación para un injerto estable y a largo plazo usando protocolos específicos para el agotamiento de los linfocitos T/B
GB2502589B (en) 2012-05-31 2019-09-11 Denso Corp Method for an in-vehicle apparatus, an in-vehicle apparatus and a vehicle
JP6361004B2 (ja) * 2012-11-05 2018-07-25 株式会社レグイミューン 免疫寛容誘導剤

Also Published As

Publication number Publication date
RU2018124303A (ru) 2020-01-13
AU2016364934A1 (en) 2018-06-07
WO2017096347A1 (en) 2017-06-08
EP3384006A1 (en) 2018-10-10
BR112018011327A2 (pt) 2018-12-04
KR20180085018A (ko) 2018-07-25
US10813949B2 (en) 2020-10-27
JP2018537472A (ja) 2018-12-20
JP2022088551A (ja) 2022-06-14
EP3384006A4 (en) 2019-06-12
CA3005767A1 (en) 2017-06-08
RU2018124303A3 (es) 2020-08-06
RU2747728C2 (ru) 2021-05-13
US20180353541A1 (en) 2018-12-13
CN108473949A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
MX2018006828A (es) Usos de poblaciones expandidas de celulas madre/progenitoras hematopoyeticas.
MX2021014956A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
MX382102B (es) Métodos mejorados para la elaboración de terapias celulares adoptivas.
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
IL275037A (en) CRISPR-CAS9-modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
MX2015013590A (es) Sistemas y metodos para la produccion dirigids de una proteina terapeutica dentro de una celula objetivo.
PH12012502328A1 (en) Methods for administering tube feed formulations
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
WO2015140648A3 (en) Glycotargeting therapeutics
BR112016024911A2 (pt) composições de proteínas solúveis e métodos de sua produçâo
MX2018008359A (es) Sistemas y métodos para preparación de plaquetas.
PH12016501705A1 (en) Immunostimulatory plasmids
SI3635096T1 (sl) Metoda za izolacijo subpopulacij srčnih matičnih celic in povezane uporabe na medicinskem področju
MY197524A (en) System of multiple bags and method for the preparation of hemocomponents
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2015123493A3 (en) Compositions and methods for modulatuion of immune response
WO2014133728A3 (en) Hhla2 as a novel inhibitor of human immune system and uses thereof
IN2014DN08964A (es)
PH12017500018A1 (en) Myo-inositol and probiotics, and their use
PH12020550651A1 (en) Gender specific synthetic nutritional compositions comprising lycopene and nutritional systems comprising them
PH12018500164A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
Bernardi et al. Post-remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age≥ 75 years: a retrospective analysis of the Rete Ematologica Lombarda
PH12018500165A1 (en) Gender specific synthetic nutritional compositions and nutritional systems comprising them
EP3324735A4 (en) Article of manufacture and methods for increasing survival of red blood cells
HK1261108A1 (en) Uses of expanded populations of hematopoietic stem/progenitor cells